Nanomi Recognized with CMO Award for Excellence in Life Science Drug Delivery

Nanomi: A Leader in Drug Delivery

Nanomi B.V., a notable subsidiary of the global pharmaceutical giant Lupin Limited, has recently distinguished itself by receiving the prestigious CMO Award for Life Science Leadership in Drug Delivery. The award was announced during the Drug, Chemical and Associated Technologies Association (DCAT) week held in New York, an event renowned for recognizing excellence in the pharmaceutical outsourcing sector.

The CMO Award is a significant recognition, awarded to top outsourcing partners based on feedback received from sponsor companies that outsource manufacturing processes. This year, for the first time, the awards were juried, emphasizing the rigorous standards and competitive nature of the selection process.

Nanomi’s innovative drug delivery methods are not merely enhancements; they are groundbreaking approaches that have set new benchmarks within the pharmaceutical industry. Dr. Shahin Fesharaki, the Global Chief Scientific Officer of Lupin, expressed that this honor underscores the commitment to advancing science and highlights the company’s efforts in improving medication delivery methods. He stated, “We remain committed to innovation that enables the delivery of high-quality medicines that significantly improve patient outcomes.” This reflects a broader dedication by Lupin Limited towards ensuring that patients receive effective healthcare solutions.

Since its establishment in 2011, the CMO Leadership Awards have been pivotal in portraying the contributions of contract manufacturing organizations to the health sector. By being recognized in this forum, Nanomi underlines its successful trajectory in the field, demonstrating a consistent focus on excellence in drug delivery.

Lupin Limited, headquartered in Mumbai, India, has made its mark across more than 100 international markets. Renowned for its diverse pharmaceutical offerings—including branded and generic formulations as well as complex generics—the company emphasizes a well-rounded approach to healthcare. Lupin’s product portfolio includes critical areas such as respiratory health, cardiovascular treatment, diabetes management, anti-infectives, and women’s health, positioning itself at the forefront of various therapy areas.

With 15 advanced manufacturing facilities and seven dedicated research centers worldwide, Lupin employs a dynamic workforce of over 23,000 professionals. The strategic partnerships and in-house capabilities contribute significantly to their ability to improve patient health outcomes. Through its subsidiaries such as Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions, the company continuously seeks ways to enhance medical solutions and distribute high-quality healthcare products.

The CMO Award not only highlights Nanomi’s achievements but also serves as motivation for the organization to further pursue innovative pathways in drug delivery. It signifies a strong commitment to revolutionizing healthcare on a global scale, advocating for solutions that prioritize patient needs effectively.

For further insights into Lupin Limited and its ventures, visit Lupin’s official website or follow them on LinkedIn. Additionally, information regarding Nanomi can be accessed through their dedicated page at Nanomi’s website and their LinkedIn profile.